References
[1] Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia
associated with the 2019 novel coronavirus indicating person-to-person
transmission: a study of a family cluster. Lancet.
2020;395(10223):514–523. doi:10.1016/S0140-6736(20)30154-9
[2] Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and
clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an
update on the status. Mil Med Res. 2020;7(1):11. Published 2020 Mar 13.
doi:10.1186/s40779-020-00240-0
[3] Li Z, Yi Y, Luo X, et al.
Development and clinical application of a rapid IgM-IgG combined
antibody test for SARS-CoV-2 infection diagnosis [published online
ahead of print, 2020 Feb 27]. J Med Virol. 2020;10.1002/jmv.25727.
doi:10.1002/jmv.25727
[4] Nissinen L, Kähäri VM. Matrix metalloproteinases in
inflammation. Biochim Biophys Acta. 2014;1840(8):2571–2580.
doi:10.1016/j.bbagen.2014.03.007
[5] McCawley LJ, Matrisian LM. Matrix metalloproteinases: they’re
not just for matrix anymore!. Curr Opin Cell Biol. 2001;13(5):534–540.
doi:10.1016/s0955-0674(00)00248-9
[6] Lerner A, Neidhöfer S, Reuter S, Matthias T. MMP3 is a reliable
marker for disease activity, radiological monitoring, disease outcome
predictability, and therapeutic response in rheumatoid arthritis. Best
Pract Res Clin Rheumatol. 2018;32(4):550–562.
doi:10.1016/j.berh.2019.01.006
[7] Hattori Y, Kida D, Kaneko A. Normal serum matrix
metalloproteinase-3 levels can be used to predict clinical remission and
normal physical function in patients with rheumatoid arthritis. Clin
Rheumatol. 2019;38(1):181–187. doi:10.1007/s10067-017-3829-9
[8] Davey A, McAuley DF, O’Kane CM. Matrix metalloproteinases in
acute lung injury: mediators of injury and drivers of repair. Eur Respir
J. 2011;38(4):959–970. doi:10.1183/09031936.00032111
[9] Health Commission of the People’s Republic of China. Notice on
the issuance of COVID-19 ’s diagnosis and treatment plan (trial version
6). Available from:http://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.htm
[10] Nerusu KC, Warner RL, Bhagavathula N, McClintock SD, Johnson
KJ, Varani J. Matrix metalloproteinase-3 (stromelysin-1) in acute
inflammatory tissue injury. Exp Mol Pathol. 2007;83(2):169–176.
doi:10.1016/j.yexmp.2007.04.003
[11] Warner RL, Beltran L, Younkin EM, et al. Role of stromelysin 1
and gelatinase B in experimental acute lung injury. Am J Respir Cell Mol
Biol. 2001;24(5):537–544. doi:10.1165/ajrcmb.24.5.4160
[12] Yamashita CM, Cybulskie
C, Milos S, Zuo YY, McCaig LA, Veldhuizen RA. The effect of matrix
metalloproteinase-3 deficiency on pulmonary surfactant in a mouse model
of acute lung injury. Can J Physiol Pharmacol. 2016;94(6):682–685.
doi:10.1139/cjpp-2015-0377
[13] Warner RL, Bhagavathula N, Nerusu KC, et al. Matrix
metalloproteinases in acute inflammation: induction of MMP-3 and MMP-9
in fibroblasts and epithelial cells following exposure to
pro-inflammatory mediators in vitro. Exp Mol Pathol.
2004;76(3):189–195. doi:10.1016/j.yexmp.2004.01.003
[14] Nissinen L, Kähäri VM. Matrix metalloproteinases in
inflammation. Biochim Biophys Acta. 2014;1840(8):2571–2580.
doi:10.1016/j.bbagen.2014.03.007
[15] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19
associated with acute respiratory distress syndrome [published
correction appears in Lancet Respir Med. 2020 Feb 25;:]. Lancet Respir
Med. 2020;8(4):420–422. doi:10.1016/S2213-2600(20)30076-X
[16] Huang C, Wang Y, Li X, et al. Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China [published
correction appears in Lancet. 2020 Jan 30;:]. Lancet.
2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
[17] Zhang Y, Yu L, Tang L, et al. A Promising Anti-Cytokine-Storm
Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification
System [published online ahead of print, 2020 Mar 20].Engineering (Beijing) . 2020;10.1016/j.eng.2020.03.006.
doi:10.1016/j.eng.2020.03.006
[18] Chen G, Wu D, Guo W, et al. Clinical and immunological features
of severe and moderate coronavirus disease 2019 [published online
ahead of print, 2020 Apr 13]. J Clin Invest. 2020;137244.
doi:10.1172/JCI137244
[19] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell
Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven
Protease Inhibitor. Cell. 2020;181(2):271–280.e8.
doi:10.1016/j.cell.2020.02.052
[20] Phillips JM, Gallagher T, Weiss SR. Neurovirulent Murine
Coronavirus JHM.SD Uses Cellular Zinc Metalloproteases for Virus Entry
and Cell-Cell Fusion. J Virol. 2017;91(8):e01564-16. Published 2017 Mar
29. doi:10.1128/JVI.01564-16